Cefpodoxime
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Cefpodoxime: From Bacterial Infections to Osteoarthritis
One-Sentence Summary
Cefpodoxime is a third-generation oral cephalosporin antibiotic, marketed in India in tablet and dry syrup forms. The TxGNN model predicts it may be effective for osteoarthritis (with rheumatoid arthritis as a second prediction), but no clinical trials and no publications were found to support this direction. The prediction is a computational signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the licence records compiled for this report |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 0.9925 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacological knowledge, cefpodoxime is a third-generation oral cephalosporin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins. This is an antibacterial action.
No established mechanistic link to osteoarthritis was identified. Cefpodoxime has no known anti-inflammatory, chondroprotective or analgesic activity relevant to this disease. The very high TxGNN score (0.9925) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
The second prediction, rheumatoid arthritis (score 0.9924), is similarly unsupported. Its autoimmune, cytokine-driven synovial inflammation is not addressed by the antibacterial mechanism, and no immunomodulatory activity is documented. The near-identical scores for the two diseases suggest a non-specific signal learned by the TxGNN model (deep learning) rather than a disease-specific rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
At least 20 single-ingredient licences are recorded and all are valid. This list may be partial. The licence records contain no approved-indication text. The five main licences are shown below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 247914 | Zerapod 50mg Dry Syrup | Bottle of 30 ml dry syrup | Not stated in licence record |
| 119398 | Kepdox 200mg Tablet | Strip of 10 tablets | Not stated in licence record |
| 202512 | Safepodox Dry Syrup | Bottle of 30 ml dry syrup | Not stated in licence record |
| 32315 | Bellocef 200mg Tablet | Strip of 10 tablets | Not stated in licence record |
| 212104 | Safydox 100mg Tablet DT | Strip of 10 dispersible tablets | Not stated in licence record |
Safety Considerations
- Drug Interactions: 78 interactions were recorded, and the 20 shown in the data compiled for this report are all rated Moderate. Main groups:
- Acid-reducing agents: famotidine, ranitidine, cimetidine, nizatidine, and the proton pump inhibitors omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole and rabeprazole
- Antacids: aluminium hydroxide, calcium carbonate, magaldrate, and magnesium carbonate, hydroxide and oxide
- Aminoglycosides: kanamycin and neomycin
- Balsalazide
Please refer to the package insert for other safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a score from the TxGNN model (deep learning). There are no clinical trials or publications for osteoarthritis, and no plausible mechanistic link to an antibacterial drug. The evidence level is L5.
To proceed, the following is needed:
- Mechanism of action data for cefpodoxime
- Package insert warnings, contraindications and approved indications from the India licences
- Preclinical or mechanistic evidence for any effect in osteoarthritis (or rheumatoid arthritis)
- A literature and trial search that directly addresses the predicted disease
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.